Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pleconaril Sanofi Synthélabo/ViroPharma.

A Billich1

  • 1Novartis Research Institute, General Dermatology, PO Box 80, Brunner Strasse 59, A-1235, Vienna, Austria. andreas.billich@pharma.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary

Pleconaril, an oral antiviral, targets picornavirus infections like viral meningitis and respiratory diseases. Development faced regulatory delays, with anticipated market entry shifting to 2001-2002.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GS-4104 Gilead Sciences Inc.

IDrugs : the investigational drugs journal·2008
Same author

Amprenavir (Vertex Pharmaceuticals Inc).

IDrugs : the investigational drugs journal·2005
Same author

Steroid sulfatase in the human hair follicle concentrates in the dermal papilla.

The Journal of investigative dermatology·2002
Same author

AIDSVAX. VaxGen.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Entecavir (Bristol-Myers Squibb).

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors.

European journal of medicinal chemistry·2001

Area of Science:

  • Virology
  • Pharmacology
  • Clinical Trials

Background:

  • Pleconaril is an oral antiviral agent under development for picornavirus infections.
  • Target indications include viral meningitis and respiratory diseases.

Purpose of the Study:

  • To summarize the development status and regulatory timeline of Pleconaril.
  • To provide an overview of clinical trial progress and market projections.

Main Methods:

  • Review of clinical trial data and regulatory filings.
  • Analysis of market forecasts and expert predictions.

Main Results:

  • Multiple Phase III trials completed or ongoing.
  • Anticipated New Drug Application (NDA) filings and potential launch dates were repeatedly revised.
  • Market projections indicated potential peak sales of $50 million in 2009.

Conclusions:

  • Pleconaril development experienced significant delays in regulatory submissions and market launch.
  • Despite setbacks, the drug showed potential for treating picornavirus infections.

Related Experiment Videos